04:50 PM EDT, 07/15/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) said Monday its KYV-101 for treating refractory stiff-person syndrome received the US Food and Drug Administration's regenerative medicine advanced therapy designation

SPS is a rare, progressive neurological autoimmune disorder that causes severe muscle stiffness in the torso, arms, and legs, affecting the ability to move and walk, the company said.

KYV-101 is an autologous CD19 chimeric antigen receptor T-cell product candidate.

Shares of Kyverna Therapeutics ( KYTX ) rose 5.9% in recent after-hours activity.

Price: 10.49, Change: +0.58, Percent Change: +5.85